Fang Wang

Dr. Fang Wang


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 August 2025 in Cardiovascular Diabetology
Verified
Journal Article
Open access
PDF file
YHYaxuan He
Yaxuan He
YCYu Cao
Yu Cao
RXRong Xiang
Rong Xiang
FWFang Wang
Fang Wang
Stroke remains a major cause of death and long-term disability worldwide, particularly in low- and middle-income countries. Early identification of individuals at high risk is essential for prevention. The stress hyperglycemia ratio (SHR), a novel indicator integrating acute and chronic glycemic states, has shown prognostic value in acute illness. However, its association with stroke risk in community populations and its potential interaction with hypertension remain unclear. This retrospective cohort study included 9682 stroke-free participants aged ≥ 45 years from the 2011 baseline of the China Health and Retirement Longitudinal Study (CHARLS), followed through 2020. SHR was calculated using fasting blood glucose and glycated hemoglobin. Participants were categorized by median SHR and hypertension status into four groups. Cox proportional hazards models were used to assess associations with incident stroke over a median follow-up of 8.43 years. Subgroup, stratified, and sensitivity analyses were performed. Predictive performance was evaluated using receiver operating characteristic (ROC) curve analysis. During 81,601 person-years of follow-up, 764 incident stroke cases were documented, with an overall incidence of 9.36 per 1000 person-years. Compared to the reference group (low SHR without hypertension), those with high SHR and hypertension had the highest stroke risk (hazard ratio: 2.94, 95% confidence interval: 2.38–3.64). SHR and hypertension were independently associated with stroke risk, and their combination demonstrated a dose-response relationship. Subgroup analyses confirmed consistent findings across sex and age strata. The combined SHR-hypertension model showed improved discriminative ability (area under the ROC curve: 0.653). Sensitivity analyses confirmed the robustness of the results. Elevated SHR is independently associated with an increased risk of stroke, and its predictive value is enhanced when combined with hypertension. SHR may serve as an integrated metabolic marker reflecting both acute stress and chronic risk burden. Incorporating SHR into stroke risk assessment tools may improve early identification and enable more targeted prevention strategies, particularly in hypertensive populations.

14 August 2019 in International Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
FWFang Wang
Fang Wang
YLYuxing Liu
Yuxing Liu
JYJingjing Yuan
Jingjing Yuan
WYWenjun Yang
Wenjun Yang
ZMZhaohui Mo
Zhaohui Mo
Objectives. The aim of this study was to investigate the effects of compound C on an in vivo mouse model of high-fat diet- (HFD-) induced obesity and hepatosteatosis. Methods. C57BL/6 mice were fed with a standard diet (n = 5) for 16 weeks and then injected saline once a day for 4 weeks as the normal chow group. Mice (n = 10) were fed with HFD for 16 weeks to induce obesity and hepatosteatosis and then divided into two groups: HFD + vehicle group injected with the vehicle solution (saline) and HFD + compound C group injected with compound C in saline (5 mg/kg i.p., once a day) for 4 weeks. Liver histology was observed. The expression levels of genes related to lipid metabolism and proinflammation in liver tissue were examined. NLRP3 inflammasome expression in liver tissue was detected by the western blot assay. HepG2 cells were pretreated with compound C and/or AICAR for 1 h and then treated with palmitic acid (PA) for 3 h. The cells were collected, and mRNA levels were determined. Results. There was a significant reduction in body-weight gain and daily food intake in the HFD + compound C group compared with the HFD + vehicle group (p<0.05). The glucose tolerance test (GTT) and insulin tolerance test (ITT) showed that compound C alleviated insulin resistance. Histology analysis showed a significant reduction of hepatic steatosis by compound C. Compound C also significantly decreased fatty acid synthesis genes, while increased fatty acid oxidation genes. Furthermore, compound C significantly reduced the expression of proinflammatory markers and NLRP3 inflammasome (p<0.05). Compound C enhanced mRNA levels of SOD1, SOD2, catalase, GPx1, and GPx4 and reduced the p-AMPK/AMPK ratio, which were stimulated by palmitic acid (PA). The effect was enhanced by AICAR. Conclusion. Our data suggest that compound C is a potent NAFLD suppressor and an attractive therapeutic target for hepatic steatosis and related metabolic disorders.

11 June 2022 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
RXRong Xiang
Rong Xiang
YLYuxing Liu
Yuxing Liu
LFLiangliang Fan
Liangliang Fan
BJBoyue Jiang
Boyue Jiang
FWFang Wang
Fang Wang

1 June 2015 in JAMA Otolaryngology–Head & Neck Surgery
Verified
Journal Article
Open access
PDF file
FWFang Wang
Fang Wang
YSYexun Song
Yexun Song
Xiaowei ZhangXiaowei Zhang
Xiaowei Zhang
GTGuolin Tan
Guolin Tan
Chronic rhinosinusitis (CRS) in children is very commonly seen in clinic and negatively affects the child’s quality of life and learning ability. Multiple factors contribute to the disease, including bacteriologic and inflammatory factors. The adenoids are a prominent contributor to this entity in the pediatric age group. The mainstay of treatment for CRS has been antibiotic therapy coupled with topical or systemic corticosteroid therapy and saline irrigation.1 Symptoms or outcomes of CRS in children were improved in half of patients or more after adenoidectomy.2 Some patients, however, have persistent symptoms despite maximum medical management and adenoidectomy, and further surgical intervention may be indicated.

12 May 2020 in Andrologia
Verified
Journal Article
Closed access
PDF file
QZQin Zhang
Qin Zhang
HHHong‐Hui He
Hong‐Hui He
MJMuhammad Usman Janjua
Muhammad Usman Janjua
FWFang Wang
Fang Wang
YYYou‐Bo Yang
You‐Bo Yang
PJPing Jin
Ping Jin

1 July 2014 in The American Journal of the Medical Sciences
Verified
Journal Article
Closed access
PDF file
LHLing Huang
Ling Huang
FZFangfang Zhang
Fangfang Zhang
YTYiting Tang
Yiting Tang
JQJiao Qin
Jiao Qin
YPYu Peng
Yu Peng
LTLijian Tao
Lijian Tao